June 2019 - Volume 3 - Issue S1 - Contributor Index

Author:
Xafaki, P.
Author:
Xagoraris, I.

PF297 COMPARISON OF RITUXIMAB DOSE-ADJUSTED EPOCH (R-DA-EPOCH) WITH RITUXIMAB-CHOP (R-CHOP) CHEMOTHERAPY IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL)

Vassilakopoulos, T.; Mellios, Z.; Verigou, E.; More

HemaSphere. 3(S1):100-101, June 2019.

PS1089 PET-SCAN FOR RESPONSE ASSESSEMENT AFTER RITUXIMAB-DOSE-ADJUSTED-EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): CLINICAL AND PROGNOSTIC SIGNIFICANCE

Vassilakopoulos, T.; Chatzidimitriou, C.; Mellios, Z.; More

HemaSphere. 3(S1):494, June 2019.

Author:
Xaus, J.
Author:
Xavier, L.

PF307 POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN LIVER AND KIDNEY TRANSPLANT RECIPIENTS OVER 33 YEARS: A SINGLE-CENTRE EXPERIENCE

Lopes, M.S.; Neto, M.; Cabral, R.; More

HemaSphere. 3(S1):106, June 2019.

Author:
Xenocostas, A.

PF410 DOUBLING TIME AFTER FIRST ATTEMPT OF IMATINIB DISCONTINUATION IS HELPFUL TO IDENTIFY THE BEST CANDIDATE FOR THE SECOND ATTEMPT FOR TREATMENT-FREE REMISSION WITH DASATINIB: CANADIAN TRAD TRIAL

Kim, D.; Busque, L.; Forrest, D.; More

HemaSphere. 3(S1):157-158, June 2019.

Author:
Xia, J.
Author:
Xia, J.T.
Author:
Xia, Q.
Author:
Xiang, X.

PS1092 TANDEM AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR TREATMENT OF ADULT T-CELL LYMPHOBLASTIC LYMPHOMA: A MULTIPLE CENTER PROSPECTIVE STUDY IN SOUTHWESTERN CHINA

Liu, Y.; Li, J.; Rao, J.; More

HemaSphere. 3(S1):495, June 2019.

Author:
Xiao, X.
Author:
Xiao, Z.
Author:
Xicoy, B.

PS1171 TELOMERE LENGTH AT DIAGNOSIS OF CHRONIC MYELOID LEUKEMIA PREDICTS THE ACHIEVEMENT OF DEEP MOLECULAR RESPONSE TO IMATINIB

Estrada, N.; Xicoy, B.; García, O.; More

HemaSphere. 3(S1):532-533, June 2019.

S840 IMPACT OF 1ST LINE TREATMENT ON OVERALL SURVIVAL IN 1.633 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA – A MULTINATIONAL COLLABORATIVE EFFORT COORDINATED BY THE AGMT STUDY GROUP

Pleyer, L.; Leisch, M.; Kouraklis, A.; More

HemaSphere. 3(S1):374-375, June 2019.

Author:
Xie, B.

PF298 LISOCABTAGENE MARALEUCEL TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA AND SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA: INITIAL RESULTS FROM TRANSCEND NHL 001

Abramson, J.; Palomba, M.L.; Arnason, J.; More

HemaSphere. 3(S1):101, June 2019.

Author:
Ximeri, M.

PS1258 CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): CLINICAL SIGNIFICANCE OF ABSOLUTE CLONAL B CELL COUNTS

Kalpadakis, C.; Pangalis, G.; Konstantinou, I.; More

HemaSphere. 3(S1):575, June 2019.

PB1881 EVALUATION OF THE QUANTITATIVE CHARACTERISTICS OF MYELOID DERIVED SUPPRESSOR CELLS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND ASSOCIATED HYPOGAMMAGLOBULINEMIA

Zavisanou, K.; Bizymi, N.; Ioneskou, K.; More

HemaSphere. 3(S1):857, June 2019.

Author:
Xing, G.
Author:
Xing, H.
Author:
Xiong, M.
Author:
Xiong, W.

PF600 IGH TRANSLOCATIONS WITH UNDEFINED PARTNERS ARE ASSOCIATED WITH SUPERIOR OUTCOME IN MULTIPLE MYELOMA PATIENTS

Mao, X.-H.; An, G.; Xu, Y.; More

HemaSphere. 3(S1):253-254, June 2019.

Author:
Xu, E.

PS1436 IFN-Α TREATMENT NORMALIZES THE PLATELET COUNTS AND REDUCES QUIESCENT STEM CELLS IN A CALR-DEL52 TRANSGENIC MOUSE MODEL, IN VIVO

Nivarthi, H.; Majoros, A.; Hug, E.; More

HemaSphere. 3(S1):662, June 2019.

Author:
Xu, J.
Author:
Xu, L.

PF485 PARTIAL RESPONSE OR BETTER AT 6 MONTHS IS PROGNOSTIC OF PROGRESSION-FREE SURVIVAL IN PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA TREATED WITH IBRUTINIB

Castillo, J.; Abeykoon, J.; Gustine, J.; More

HemaSphere. 3(S1):194-195, June 2019.

PS1531 INCIDENCE, RISK FACTOR AND OUTCOME OF IMMUNE-MEDIATED NEUROPATHIES FOLLOWING HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL TRANSPLANTATION

Ren, X.; Liu, X.; Huang, Q.; More

HemaSphere. 3(S1):706-707, June 2019.

Author:
Xu, L.-P.

PF218 DDX11 MUTATIONS AND CLONAL TRAJECTORY PATTERNS IN ADULTS WITH CYTOGENETICALLY-NORMAL ACUTE MYELOID LEUKEMIA

Zhou, Y.-L.; Wu, L.-X.; Wang, Z.-L.; More

HemaSphere. 3(S1):61, June 2019.

PS1558 COMPARISON OF THE INCIDENCE AND OUTCOMES OF TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY BETWEEN HAPLOIDENTICAL AND MATCHED SIBLING DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION

Gui, R.-Y.; Liu, X.; Su, Y.; More

HemaSphere. 3(S1):718-719, June 2019.

PB2361 INCIDENCE, RISK FACTORS AND OUTCOMES OF SINUSOIDAL OBSTRUCTION SYNDROME AFTER HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION

Cai, X.; Wu, J.; Gui, R.-Y.; More

HemaSphere. 3(S1):1052, June 2019.

Author:
Xu, Q.

PS1051 FT-2102, AN IDH1 M INHIBITOR, INDUCES MUTATION CLEARANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) TREATED IN PHASE 1 DOSE ESCALATION AND EXPANSION STUDY

Botton, S. De; Watts, J.; Baer, M.; More

HemaSphere. 3(S1):475-476, June 2019.

Author:
Xu, R.
Author:
Xu, W.

PF207 TARGETING WILMS TUMOR 1 WITH A T CELL BISPECIFIC ANTIBODY (WT1-TCB): EX VIVO AND IN VIVO POTENCY BY BIVALENT RECOGNITION OF PEPTIDE-MHC COMPLEXES FROM AN INTRACELLULAR TUMOR ANTIGEN

Augsberger, C.; Klein, C.; Heitmüller, C.; More

HemaSphere. 3(S1):56, June 2019.

PS1460 LONG-TERM FOLLOW UP OF JAK INHIBITOR (JAKI) TREATED PATIENTS WITH MYELOFIBROSIS: IMPACT OF MOLECULAR ENHANCED INTEGRATED SCORING SYSTEMS AND TYPE OF JAKI THERAPY FAILURE ON SURVIVAL

Mcnamara, C.; Spiegel, J.; Xu, W.; More

HemaSphere. 3(S1):672-673, June 2019.

Author:
Xu, X.
Author:
Xu, Y.

PF600 IGH TRANSLOCATIONS WITH UNDEFINED PARTNERS ARE ASSOCIATED WITH SUPERIOR OUTCOME IN MULTIPLE MYELOMA PATIENTS

Mao, X.-H.; An, G.; Xu, Y.; More

HemaSphere. 3(S1):253-254, June 2019.

Show: